In a significant undertaking by Kim et al, researchers embarked on contrasting the outcomes of neoadjuvant endocrine therapy (NET) with those of NCT in pre-menopausal patients diagnosed with ER-positive, HER2-negative, lymph node-positive BC.51 Sourced from seven hospitals in South Korea, the patients in their study, who underwent 24 weeks of either therapeutic regimen, painted a decisive picture: those under NCT displayed a markedly higher clinical response rate of 83.7% versus the 52.9% in the NET cohort. This evidence concerns the gene ERBB2 and breast cancer.